Ccr2 deletion dissociates cavity size and tau pathology after mild traumatic brain injury

Stefka Gyoneva1,3,4*, Daniel Kim2,3, Atsuko Katsumoto1,3, O. Nicole Kokiko-Cochran1,3, Bruce T. Lamb1,3 and Richard M. Ransohoff1,3,4*

Abstract

Background: Millions of people experience traumatic brain injury (TBI) as a result of falls, car accidents, sports injury, and blast. TBI has been associated with the development of neurodegenerative conditions such as Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). In the initial hours and days, the pathology of TBI comprises neuronal injury, breakdown of the blood–brain barrier, and inflammation. At the cellular level, the inflammatory reaction consists of responses by brain-resident microglia, astrocytes, and vascular elements as well as infiltration of peripheral cells. After TBI, signaling by chemokine (C-C motif) ligand 2 (CCL2) to the chemokine (C-C motif) receptor 2 (CCR2) is a key regulator of brain infiltration by monocytes.

Methods: We utilized mice with one or both copies of Ccr2 disrupted by red fluorescent protein (RFP, Ccr2<sup>RFP+/+</sup> and Ccr2<sup>RFP/RFP</sup>). We subjected these mice to the mild lateral fluid percussion model of TBI and examined several pathological outcomes 3 days later in order to determine the effects of altered monocyte entry into the brain.

Results: Ccr2 deletion reduced monocyte infiltration, diminished lesion cavity volume, and lessened axonal damage after mild TBI, but the microglial reaction to the lesion was not affected. We further examined phosphorylation of the microtubule-associated protein tau, which aggregates in brains of people with TBI, AD, and CTE. Surprisingly, Ccr2 deletion was associated with increased tau mislocalization to the cell body in the cortex and hippocampus by tissue staining and increased levels of phosphorylated tau in the hippocampus by Western blot.

Conclusions: Disruption of CCR2 enhanced tau pathology and reduced cavity volume in the context of TBI. The data reveal a complex role for CCR2<sup>+</sup> monocytes in TBI, as monitored by cavity volume, axonal damage, and tau phosphorylation.

Keywords: Traumatic brain injury, CCR2, Tau, MAPT, Monocyte

Background

Traumatic brain injury (TBI) is a common condition in today’s society. It is variable in extent and circumstance and imposes enormous suffering and expense. The injury can be sustained in a single event or in a repetitive fashion, can be either closed head or penetrating, and ranges in severity from mild to severe. About 75% of TBI is closed head in nature and mild in intensity [1]. Further contributing to patient suffering and impact on society, TBI is linked to the development of neurodegenerative conditions. For example, TBI of varying intensity is associated with increased risk or earlier onset of Alzheimer’s disease (AD), and repetitive mild TBI is associated with chronic traumatic encephalopathy (CTE) [2–8].

One common pathological feature of TBI, AD, and CTE is the hyperphosphorylation and mislocalization of the microtubule-associated protein tau (MAPT, here termed tau) [9]. Tau contains numerous potential phosphorylation sites and is a target of multiple kinases. In physiological conditions, tau is phosphorylated at a few sites and is located in axons where it binds to microtubules to stabilize the axonal cytoskeleton. However, in pathological conditions, tau can be phosphorylated at multiple additional sites. The (hyper)phosphorylated tau (pTau) dissociates from microtubules in the axon, translocates to the cell body and proximal dendrites, and...
aggregates in structures termed neurofibrillary tangles, leading to impaired axonal function [9]. While the mechanisms driving tau phosphorylation and tangle formation are not well established, there is substantial evidence suggesting that inflammation can promote this process [10–12].

A prominent feature of TBI is the development of an inflammatory reaction within minutes of the injury event [13–17]. Cells at the site of injury secrete cytokines and chemokines that lead to the recruitment of peripheral immune cells—initially neutrophils, which are quickly replaced by monocytes. Concurrently, there is activation of brain-resident astrocytes and microglia. The inflammatory reaction could contribute to the progression of axonal pathology and tissue damage and is thus a potential target to ameliorate TBI pathology [13, 17, 18].

Although inflammation increases tau phosphorylation and pTau is detected in central nervous system (CNS) tissues of TBI patients and in animal models, whether post-injury inflammation affects pTau levels in the context of TBI has not been addressed. Here, we used the lateral fluid percussion injury (LFPI) model of TBI to study how modulation of the mononuclear reaction after TBI influences tau phosphorylation. In the context of TBI, the mononuclear population is primarily represented by CD45hiCX3CR1hiCCR2− microglia, CD45hiCX3CR1loCCR2hi inflammatory monocytes, and CD45loCX3CR1hiCCR2lo patrolling monocytes [21–24], but perivascular and meningeal macrophages may also play a role. We employed mice deficient for either chemokine (C-X3-C motif) receptor 1 (Cx3cr1<sup>GFP/GFP</sup>) mice or chemokine (C-C motif) receptor 2 (Ccr2<sup>RFP/RFP</sup>) mice. Ccr2<sup>RFP/RFP</sup> mice display reduced infiltration of Ly6ci inflammatory monocytes into the brain after TBI [25]. Here, Cx3cr1<sup>GFP/GFP</sup> mice showed no difference in TBI pathology compared to wild type (WT) mice, but Ccr2<sup>RFP/RFP</sup> mice had reduced lesion volume and axonal pathology. Surprisingly, Ccr2<sup>RFP/RFP</sup> mice also exhibited increased levels and mislocalization of pTau in the cortex and hippocampus, suggesting that monocyte-dependent inflammation exerts distinct effects on tissue loss as compared to tau phosphorylation after TBI.

Methods

Animals and TBI induction

All procedures performed on animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic. We employed two mouse strains (Cx3cr1<sup>GFP/GFP</sup> and Ccr2<sup>RFP/RFP</sup>) that allowed us to manipulate the cellular reaction after TBI and at the same time visualize the inflammatory cells of interest [26]. Cx3cr1<sup>GFP/GFP</sup> mice (green fluorescent protein (GFP) expression in microglia and patrolling CCR2<sup>lo</sup> monocytes) were maintained on the Ccr2<sup>RFP/RFP</sup> background in which only one copy of Ccr2 is disrupted (red fluorescent protein (RFP) expression in inflammatory CCR2<sup>hi</sup> monocytes, some T cells). Similarly, for some experiments Ccr2<sup>RFP/RFP</sup> mice were maintained on the Cx3cr1<sup>GFP/GFP</sup> background. There were no statistical differences in the responses to TBI by Ccr2<sup>RFP/RFP</sup>; Cx3cr1<sup>+/+</sup> and Ccr2<sup>RFP/RFP</sup>; Cx3cr1<sup>GFP/+</sup> mice (data not shown) and the two genotypes were pooled together for analysis. Microglia were identified by Iba1 staining in Ccr2<sup>RFP/RFP</sup> mice at 3 days post injury (dpi), before other cell types have upregulated Iba1 expression [27].

To induce TBI, we performed lateral fluid percussion injury as described before [19]. Briefly, 8–10-week-old male and female mice were anesthetized with 100 mg/kg ketamine/10 mg/kg xylazine; the fur on top of the head was shaved, and the skin was cut and moved to the side. A craniotomy with ~3 mm diameter was opened on the right side of the central suture, halfway between Bregma and Lambda, without disturbing the underlying dura mater. A modified Leur-Lok hub was placed around the craniotomy and sealed in place with dental acrylic. The mice were allowed to recover from anesthesia and returned to their home cages. On the next day, the mice were anesthetized again and attached to a fluid percussion device (AmScien Instruments FP-302) by the Leur-Lok hub. The device was calibrated to deliver mild injury with pressure intensities between 0.4 and 0.6 atm. After injury, the hub was removed, the skin was sutured, and mice were returned to their home cages to recover. For all experiments, the mice were euthanized 3 dpi.

Tissue staining

Tissue staining was used to evaluate the extent of the inflammatory reaction after TBI, lesion volume, axonal pathology, and tau phosphorylation and localization. At 3 dpi, mice were deeply anesthetized with ketamine/xylazine and perfused with ice-cold phosphate-buffered saline (PBS) followed by 4 % paraformaldehyde (PFA) in PBS. The brains were isolated and postfixed in 4 % PFA overnight and sectioned on a sliding microtome at 30 μm thickness. During staining, all washes were performed three times for 5 min each in 0.1 % triton X-100 in PBS. Antibody solutions were prepared in PBS unless otherwise noted.

To visualize the inflammatory reaction after TBI, serial sections spaced 150 μm apart and spanning ~4 mm thickness around the injury cavity were blocked in 10 % normal goat serum (NGS) and stained overnight at 4 °C with mouse anti-GFP (UCDavis/NIH Neuro-Mab Facility #75-132, 1:8000 dilution), or rabbit anti-Iba1 (Wako #019-19741, 1:1000) antibodies to identify microglia, and rabbit or rat anti-RFP (Abcam #ab62341, 1:1000 and Chromotek # 5 F8 α-Red, 1:1000, respectively) antibodies to identify infiltrating monocytes. The secondary antibodies (Goat anti-mouse-Alexa 488, Invitrogen
Axonal pathology was assessed with amyloid precursor protein (APP) staining which accumulates in axonal swellings of damaged neurons [28]. The sections were incubated in 0.3 % H2O2 for 30 min at RT to inactivate endogenous peroxidases. Antigen retrieval was performed in 1× Target retrieval solution (Dako Cytomation #S1699) containing 0.5 % Tween in PBS at 95 °C for 10–15 min. After blocking in 10 % NGS, primary rabbit anti-APP antibody (Invitrogen #51-2700) was applied overnight at 4 °C and secondary biotinylated goat anti-rabbit antibody (Vector BA-1000) was applied for 1 h at RT. The signal was detected using the ABC Elite Kit (Vector PK-6100) and DAB substrate kit (Vector SK-4100) according to the manufacturer’s instructions. Sections were allowed to dry and coverslipped with hardset mounting medium (Fisher Scientific #SP15).

For phosphorylated tau, after antigen retrieval and blocking in 5 % NGS and 0.3 % Triton X-100 in PBS for 2 h at RT, the localization of pTau was detected with the mouse anti-AT8 antibody (ThermoScic m1n1020, 1:500 dilution in 5 % NGS, 0.3 % Triton X-100 in PBS) overnight at 4 °C. The secondary antibody used, goat anti-mouse-Alexa 647 (Invitrogen #A21235, 1:1000 dilution), was chosen not to interfere with the signal of genetically encoded GFP and RFP and was applied for 1 h at RT. The sections were mounted on glass slides and coverslipped with VectaShield with DAPI medium (Vector H-1200).

**Imaging and image quantification**

Sections stained with GFP (or Iba1) and RFP were imaged on a Leica CTR5500 microscope equipped with a QImaging Retiga Exi FAST 1394 MONO camera at 10× magnification. Tiling of consecutive fields of view was employed to capture the whole section and all sections from a mouse using ImagePro Plus software to drive the microscope. Both GFP/Iba1 (microglia) and RFP (monocyte) channels were recorded. The resulting images were then analyzed with ImageJ software (National Institutes of Health) to calculate (1) lesion cavity volume, (2) the volume of brain tissue (in 4 mm slab) occupied by microglial immunoreactivity, and (3) volume of brain tissue occupied by monocyte immunoreactivity. Initially, each slice was manually outlined; for slices with a TBI-induced cavity, the “whole slice” outline was generated based on where the tissue would be if it were not missing. Then, the cavity, the region around the cavity with increased GFP/Iba1 immunoreactivity, and the region around the cavity with increased RFP immunoreactivity were manually outlined for each brain section. Finally, all sections (~22) for an animal were multiplied by the distance between sections (150 µm) and summed up to obtain the corresponding volumes (cavity, microglia, and monocyte immunoreactivity) as a percentage of the brain volume analyzed (4 mm thickness).

APP-stained sections were also imaged with tiling but in brightfield mode. To quantify axonal damage, the corpus callosum in the ipsilateral side to the injury was manually outlined in ImageJ and the percentage of the corpus callosum with APP immunoreactivity above threshold was calculated. Two sections were stained for each animal and averaged after quantification.

**Western blot and pTau quantification**

pTau levels after TBI were quantified by Western blot. TBI and sham mice were anesthetized with ketamine/xylazine at 3 dpi and perfused with ice-cold PBS. Naïve mice that did not undergo any surgery were used as a control for the effect of surgery itself; naïve mice were simply anesthetized and perfused. The brains were isolated, the ipsilateral and contralateral hemispheres were separated (right and left for naïve mice), and the cortices and hippocampi were microdissected from each hemisphere. Tissues were homogenized in Tissue Protein Extraction Reagent (Pierce #78150) containing 1 % each of protease and phosphatase inhibitors (Sigma #P8340 and #P5726, respectively).

Fifty nanograms of total protein were separated on 4–12 % bis-tris gels (Invitrogen #NP0322) and transferred to 0.45 μm PVDF membranes (Millipore #IPFL10100). Separate membranes were run for the detection of phosphorylated tau (with mouse anti-AT8 antibody, 1:5000 dilution) and total tau (mouse anti-Tau5 antibody, Invitrogen #ahb0042. 1:5000). After running, the membranes were activated in methanol, blocked, and incubated in primary antibodies overnight at 4 °C. GAPDH (Trevigen #2275-PC-100, 1:10,000) was used as loading control on all membranes. Proteins were detected with goat anti-mouse IRDye 800CW (for AT8 or Tau5, Li-Cor #926-68171) and goat anti-rabbit IRDye 680RD (for GAPDH, Li-Cor #827-08364) fluorescent antibodies.
Images of the developed membranes were acquired on a Li-Cor Odyssey CLx imager.

To quantify the relative levels of pTAU across samples, the channels for tau and GAPDH were split and analyzed separately with the ImageJ Gel tool. Both AT8 and Tau5 signals were first normalized to GAPDH to ensure equal sample loading. Then, the relative AT8 signal was normalized to total tau. There were no significant differences in total tau between samples after TBI (data not shown).

Statistical analysis
Data points on the graphs represent individual mice. The average and standard error of the mean are also shown. The effects of genotype and injury intensity were examined by two-way analysis of variance (ANOVA); statistical differences between groups were determined with Tukey’s *post hoc* tests. All significant values in *post hoc* tests were adjusted for multiple comparisons. Groups were considered to be statistically different if *p* < 0.05 for both factor effect (in ANOVA) and *post hoc* tests.

Results
Preventing CCR2⁺ monocyte infiltration after TBI reduces lesion pathology
The inflammatory reaction is a common feature of TBI. Here, we addressed how modulating monocyte inflammation might affect pathological features of neurodegeneration. We altered the inflammatory reaction in two different ways: by inactivation of Cx3cr1 (in Cx3cr1<sup>GFP/GFP</sup> mice), which affects the activation of brain-resident microglia [29] and Ly6C<sup>lo</sup> patrolling monocytes, or by inactivation of Ccr2 (in Ccr2<sup>RFP/RFP</sup> mice), which reduces the infiltration of Ly6C<sup>hi</sup> inflammatory monocytes and a subset of T cells into the brain after TBI [25]. Intercrossing these two mouse strains allowed us to not only inactivate the genes of interest, but also directly visualize chemokine (C-X3-C motif) receptor 1 (CX3CR1)- and CCR2-positive cells in tissue sections [26]. CX3CR1<sup>+</sup> patrolling monocytes and CCR2<sup>+</sup> T cells represent only a small proportion of infiltrating cells after TBI compared to CX3CR1<sup>+</sup> microglia and CCR2<sup>+</sup> inflammatory monocytes, respectively (data not shown). Hence, we herein refer to GFP-positive cells as microglia and RFP-positive cells as infiltrating inflammatory monocytes. Ccr2<sup>RFP/RFP</sup>, Cx3cr1<sup>GFP/GFP</sup>, and control double-heterozygous mice were subjected to mild LFPI, and the inflammatory reaction and cavity pathology were analyzed 3 dpi from brain sections spanning a 4-mm portion of the brain that encompassed the whole lesion area (Fig. 1). As expected, the injury induced microglial morphological transformation (seen as increased GFP/Iba1 signal) and infiltration of hematogenous monocytes (presence of RFP<sup>+</sup> cells) at the site of damage in control double-heterozygous Cx3cr1<sup>GFP/+</sup>, Ccr2<sup>RFP/+</sup> mice (Fig. 1a). The increased GFP signal and presence of RFP<sup>+</sup> cells were mostly restricted to the site of tissue damage and brain cavitation. Moreover, the GFP<sup>+</sup> cells had mainly ramified, bushy, morphology, suggesting that at this early time point, these cells were likely activated microglia rather than infiltrating CX3CR1<sup>+</sup> monocytes. Interestingly, although care was taken not to disturb the dura mater and underlying brain during craniotomy, the “sham” surgery itself induced a low level of microglial activation and monocyte infiltration (Fig. 1a). Consistent with previous studies [23, 30], deletion of Ccr2 prevented the infiltration of peripheral CCR2-positive cells into the brain after TBI as evident by the absence of RFP<sup>+</sup> cell staining at the injury site (Fig. 1b). However, there was still prominent microglial reaction as monitored by GFP or Iba1 staining (Fig. 1b). In contrast, neither microglial activation nor monocyte infiltration in response to TBI appeared altered in Cx3cr1<sup>GFP/GFP</sup> mice at 3 dpi (Fig. 1c).

We quantified the inflammatory reaction and the cavity pathology by calculating the percentage of the brain parenchyma (in a 4-mm brain portion around the injury) that was occupied by reactive microglia, infiltrating monocytes or size of tissue cavity (Fig. 2). Both injury and genotype had a significant effect on the cavity volume (Fig. 2a; two-way ANOVA, *p* < 0.001 for Injury and *p* < 0.05 for Genotype) and mononcytic reaction (Fig. 2b; two-way ANOVA, *p* = 0.0010 for Injury and *p* < 0.01 for Genotype), but there was no significant change in the microglial reaction under any conditions examined (Fig. 2c; two-way ANOVA, *p* = 0.0501 for Injury and *p* = 0.1116 for Genotype). Consistent with the tissue staining (Fig. 1), Ccr2 deletion resulted in a significant decrease in cavity volume (Fig. 2a; two-way ANOVA and Tukey’s *post hoc* test, *p* < 0.05 compared to heterozygous control) and portion of the brain parenchyma containing monocytes (Fig. 2b; two-way ANOVA and Tukey’s *post hoc* test, *p* < 0.05 compared to heterozygous control). Despite this, there was no change in the microglial reaction in Ccr2<sup>RFP/RFP</sup> mice (Fig. 2c; two-way ANOVA and Tukey’s *post hoc* test, *p* = 0.9606).

Deletion of Cx3cr1 did not affect the inflammatory reaction or cavity volume when comparing knockout to heterozygous mice (Fig. 2a–c; two-way ANOVA and Tukey’s *post hoc* test, *p* = 0.2205 for cavity volume, *p* = 0.0781 for mononcytic reaction, and *p* = 0.1463 for microglial reaction). Because Cx3cr1 deletion did not affect either the inflammatory reaction or cavity volume after mild injury here, we continued all subsequent studies only with Ccr2<sup>RFP/RFP</sup> mice and appropriate controls.

Ccr2 deletion reduces TBI-induced axonal pathology
After TBI, axonal pathology is characterized by APP-positive axonal swellings and axonal retraction bulbs.
indicating axotomy at sites remote to the injury [28]. In the present study, we detected increased APP immunoreactivity, especially in the corpus callosum underlying the injury site at 3 dpi (Fig. 3a). Examining the corpus callosum at higher magnification showed that many of the APP-positive structures seemed to align with the direction of axonal tracts (Fig. 3b). Deletion of Ccr2 appeared to reduce APP immunoreactivity after TBI. Quantifying axonal pathology as the percentage of the corpus callosum with APP immunoreactivity confirmed reduced axonal pathology in Ccr2^{RFP/RFP} mice at 3 dpi compared to controls (Fig. 3c; two-way ANOVA and Tukey's post hoc test, p < 0.05).

**Ccr2 deletion alters tau phosphorylation and localization**

Because inflammation has been shown to modulate tau pathology and Ccr2 deletion reduces monocyte-mediated inflammation after TBI [10–12, 23, 30], we examined the effect of TBI on tau phosphorylation in Ccr2^{RFP/RFP} mice. We initially analyzed changes in tau phosphorylation by
fluorescent immunohistochemistry to determine the localization of pTau (Fig. 4). Tissue staining for the AT8 pTau epitope showed increased staining at the site of injury in the cortex of both control heterozygous and Ccr2<sup>RFP/RFP</sup> mice (Fig. 4a). While the pTau immunoreactivity at the lesion site appeared rather diffuse in heterozygous mice, pTau signal was mostly perinuclear in Ccr2<sup>RFP/RFP</sup> mice (Fig. 4c). It should be noted that the physiological location of tau is in the axon; hence, both increased phosphorylation and mislocalization to the cell soma after TBI are abnormal.

Increased tau phosphorylation was also detected remote to the injury at 3 dpi, in the underlying hippocampus in both control and Ccr2<sup>RFP/RFP</sup> mice (Fig. 4b). However, the pattern of pTau immunoreactivity appeared different in the two genotypes. As in the cortex, AT8 immunoreactivity in the hippocampus of heterozygous Ccr2<sup>RFP/+</sup> TBI mice was mostly diffuse and located in the hilus of the dentate gyrus, outside the granule cell layer. In contrast, AT8 signal in the hippocampus of Ccr2<sup>RFP/RFP</sup> mice was the highest around cell bodies in the granule cell layer of the dentate gyrus and hilus (Fig. 4b, c). Thus, TBI increases tau phosphorylation in both control and Ccr2<sup>RFP/RFP</sup> mice, but only Ccr2<sup>RFP/RFP</sup> mice show clear pTau translocation to the cell soma.

Both injury and Ccr2 genotype affect pTau levels by Western blot

In order to quantify the changes in pTau after TBI, we performed Western blot analysis for the AT8 pTau epitope in microdissected cortical or hippocampal lysates. Because the hub-placement surgery itself influenced the inflammatory reaction (Fig. 1) and pTau immunoreactivity (Fig. 4a, compare sham ipsilateral and contralateral staining), we also included treatment-naïve mice that did not undergo surgery but received ketamine/xylazine anesthesia. Interestingly, there was not an injury- and side-dependent increase in pTau levels in the cortex at 3 dpi (Fig. 5a). Yet, mice with both sham surgery and mild LFPI exhibited higher AT8 pTau levels than naïve mice in a side-independent manner (Fig. 5a). The levels of pTau were also modulated differentially in the hippocampus. While hub-placement surgery did not affect pTau in control mice, they increased pTau in Ccr2<sup>RFP/RFP</sup> mice in a “dose”- and side-dependent manner. That is, even surgery itself led to higher pTau on the ipsilateral side compared to naïve mice, and the higher “dose”—mild injury—led to an even larger increase in pTau (Fig. 5b).

We quantified pTau levels on the ipsilateral and contralateral sides separately in order to evaluate the effects of injury intensity and genotype (Fig. 6). In the ipsilateral cortex, both injury and genotype had a significant effect on pTau levels (Fig. 6a; two-way ANOVA, p < 0.01 for Injury and p < 0.001 for Genotype). Overall, Ccr2 deletion resulted in higher pTau levels after experimental manipulation of the mice. There was a significant increase in p Tau in Ccr2<sup>RFP/RFP</sup> mice in sham (surgery) mice compared to naïve mice (two-way ANOVA and Tukey’s post hoc test, p < 0.01) but not an additional
increase after mild injury (Fig. 6a). There was a significant difference between control and Ccr2<sup>RFP/RFP</sup> mice only for the sham surgery groups (Fig. 6a; two-way ANOVA and Tukey’s post hoc test, p < 0.01). Despite the change in pTau immunoreactivity in tissue staining (Fig. 4), there was not a significant difference after injury in pTau levels in control heterozygous mice (Fig. 6a). Ccr2<sup>RFP/RFP</sup> mice were also significantly different from control mice on the contralateral side of the cortex (two-way ANOVA, p < 0.05), but there were no significant inter-group changes (Fig. 6b).

Consistent with tissue staining (Fig. 4b), we detected robust changes in pTau levels in the hippocampus on both the ipsilateral and contralateral sides (Fig. 6c, d), with both injury and genotype having significant effects (two-way ANOVA, p < 0.0001 for Genotype for both the ipsilateral and contralateral sides, p < 0.01 and p < 0.05 for Injury intensity for the ipsilateral and contralateral sides, respectively). There was a significant difference in pTau levels after mild injury between control heterozygous and Ccr2<sup>RFP/RFP</sup> mice (two-way ANOVA and Tukey’s post hoc test, p < 0.0001 for both sides). As in the cortex, the sham surgery induced an increase in pTau in Ccr2<sup>RFP/RFP</sup> mice compared to naïve mice that was not subsequently increased by mild injury (Fig. 6c, d; two-way ANOVA and Tukey’s post hoc test, p < 0.0001 and p < 0.01 comparing naïve and mild injured Ccr2<sup>RFP/RFP</sup> mice on the ipsilateral and contralateral sides, respectively). Experimental manipulation or surgery did not significantly affect pTau levels in control heterozygous mice. Thus, Ccr2 deletion resulted in increased pTau levels on both the ipsilateral and contralateral sides at 3 days after injury or sham surgery.
Discussion

The inflammation that develops after TBI has the potential to influence subsequent neuronal pathology [14, 18]; preventing or mitigating aspects of inflammation could help prevent secondary tissue damage and promote recovery [17]. Because inflammation is also a feature of many neurodegenerative conditions, we wanted to examine if modulating inflammation will also affect aspects of neurodegeneration such as altered Tau phosphorylation. We initially examined two models of altered inflammation: deletion of the chemokine receptor CX3CR1, which primarily affects microglia in the brain, and deletion of the chemokine receptor CCR2, which primarily affects bone marrow-derived monocytes and their extravasation to sites of damage [25, 29]. Only reduced monocyte infiltration through Ccr2 deletion reduced cavity volume and axonal pathology (Figs. 1, 2, and 3), which led us to examine its effects on tau phosphorylation. Surprisingly, despite the reduced accumulation of monocytes at 3 dpi, Ccr2^RFP/^RFP mice showed increased pTau levels by both tissue staining and Western blot analyses (Figs. 4, 5, and 6). Moreover, pTau was translocated from the axon to the cell body in both the cortex and hippocampus of Ccr2^RFP/^RFP mice (Fig. 4). The pathology...
seen in TBI mice here is reminiscent to the neurofibrillary
tangles seen in human tauopathies [31] and in patients
with CTE or after a single TBI event [3, 32, 33].

Modulation of inflammation in Cx3cr1<sup>GFP/GFP</sup> and
Ccr2<sup>RFP/RFP</sup> mice

The Cx3cr1<sup>GFP/GFP</sup> mice that we employed here are com-
monly used to study and visualize microglia in the brain
[29, 34]. Indeed, parenchymal microglia are the predomin-
ant cell type expressing CX3CR1—and GFP—in the brain
as peripheral CX3CR1-positive cells do not cross the in-
tact blood–brain barrier (BBB) in physiological conditions.
However, disruption of the BBB in TBI will allow periph-
eral CX3CR1<sup>+</sup> cells to enter the brain. In a dorsal column
 crush model of spinal cord injury, CX3CR1<sup>+</sup> “patrolling”
monocytes mediate axonal pathology [35]. In our studies,
the great majority of GFP<sup>+</sup> cells after TBI had ramified or
bushy morphology (Fig. 1), suggesting that they are micro-
glia. Yet, additional studies are necessary to establish the
ontology of all GFP<sup>+</sup> cells after TBI.

Delivery of mild TBI to Cx3cr1<sup>GFP/GFP</sup> mice did not
significantly affect any of the pathological signs we ex-
amined: microglial activation, recruitment of CCR2<sup>+</sup>
cells, or lesion cavity, which was in contrast to the clear
effect of Ccr2 deletion (Figs. 1 and 2). Thus, we focused
on CCR2 signaling rather than CX3CR1 signaling in
subsequent analyses. It should be noted that microglial
CX3CR1 signaling has been shown to affect tau
phosphorylation in models of tauopathy. Specifically,
deletion of Cx3cr1 or its ligand Cx3cl1 results in in-
creased tau phosphorylation in mice overexpressing hu-
man tau or the APPPS1 model of AD [11, 36, 37].
Hence, it is plausible that Cx3cr1 deletion might lead to
changes in tau phosphorylation in our mild TBI model,
but this question remains to be addressed.

As with Cx3cr1<sup>GFP/GFP</sup> mice, Ccr2<sup>RFP/RFP</sup> mice are sim-
plistically used to study responses by inflammatory
CD45<sup>hi</sup>Ly6C<sup>hi</sup> monocytes [25, 26]. However, subsets of T
cells, NK cells, and Ly6C<sup>lo</sup> monocytes express CCR2 or
the RFP reporter in some conditions [26]. Although the
frequency of these other CCR2/RFP<sup>+</sup> cells is significantly
lower than the frequency of CCR2<sup>+</sup> inflammatory mono-
cytes after TBI [24], we cannot rule out that these cell
types contribute to the pathology. Thus, additional stud-
ies will be necessary to carefully phenotype the different
lymphoid populations that respond to TBI and their role
in TBI outcomes.

Tau phosphorylation after TBI

There is ample evidence that phosphorylated, aggregated
tau is present in the brain of humans that had suffered
from various tauopathies, including CTE, AD, frontotem-
poral dementia, Pick’s disease, and others [31]. In the
context of TBI, pTau has been observed in numerous indi-
viduals who had experienced traumatic events ranging
from repetitive sports-related injuries to isolated head
traumas (for examples, see 32, 3). Yet, there are only a
handful of studies that have examined tau phosphorylation
in animal models of TBI. In two different transgenic tau-overexpressing animals, TBI accelerates tau pathology [38, 39]. Using wild type mice, Genis et al. [40] and Iliff et al. [41] show that TBI can cause tau hyperphosphorylation in the absence of mutated transgene expression. However, although Genis et al. [40] suggest that tau phosphorylation is transient, peaking at 4 h, Iliff et al. [41] demonstrate increased levels of pTau in the brain even at 28 days after injury. Similar to our study, they found that increased tau phosphorylation is not restricted to the injured ipsilateral side, but is also detectable to the contralateral side.

Another noteworthy observation from our study is that the surgery that is required to prepare mice for fluid percussion injury is sufficient to increase pTau levels when compared to treatment-naïve mice. Furthermore, certain types of anesthetics quickly increase the levels of pTau in the brain [42–44]. In our study, all groups received anesthesia, including the treatment-naïve mice. Thus, the effects of anesthesia alone are not sufficient to explain the increase of pTau after surgery and injury. Yet, these findings suggest that tau phosphorylation may represent an immediate physiological response to brain disturbances or a biomarker of altered brain homeostasis. It is worth investigating if tau becomes phosphorylated in other conditions in which brain function is impaired, such as stroke, epilepsy, etc. Moreover, although pTau is more prone to aggregation [9], it remains to be determined if it serves physiological functions that may be aimed at returning the brain to homeostasis in the acute time scales.

We were not able to detect a significant increase in pTau levels after mild injury compared to the surgery itself. One possibility for this is that the surgery and Ccr2 genotype synergized to produce a strong pTau signal, and the deletion of Ccr2 itself sensitizes the mice to anesthesia- or surgery-mediated effects on pTau. Then, the delivery of an additional injury with mild intensity may not be sufficient to substantially increase pTau levels (Fig. 6). However, despite the lack of protein increase by Western blot, the injury does induce pTau translocation from the axon to the cell body (Fig. 4). As a result, surgery (or other brain disturbances) and traumatic injury may play distinct, sequential roles to lead to frank tau pathology.

Ccr2 modulation in TBI
Preventing monocyte accumulation in the brain has become a promising therapeutic approach to treat TBI and prevent the development of secondary pathologies. Deletion of Ccl2, a ligand for CCR2, Ccr2 itself or antagonism of CCR2 with small molecules have all been shown to be beneficial after TBI [23, 30, 45–47]. Importantly,
interfering with CCR2 signaling results in improved cognitive function for up to 4 weeks after the injury.

Yet, here we show that Ccr2 deletion also leads to increased phosphorylation of tau protein—an event that is commonly associated with loss of physiological function and gain of pathological function by tau in a variety of neurodegenerative diseases [31]. In many of these conditions, tau is found in hyperphosphorylated form in the cell body of neurons, similar to what we observed here after TBI in Ccr2<sup>REF</sup>/<sup>RFP</sup> mice. This raises the question whether interfering with CCR2 signaling might have unexpected consequences of promoting the development of pathologies.

There are still important questions that need to be addressed about the role of CCR2 signaling in tau pathology after TBI. First, are the effects of Ccr2 deletion on tau phosphorylation long lasting or transient? Second, are other disease-associated epitopes of pTau, such as AT180, PHF-1, or CP13, affected? The work by Lifft et al. [41] suggests that tau phosphorylation could persist for at least 28 days after TBI and affect a variety of pTau epitopes. Finally, how can the absence of a peripheral cell type, which is normally not found in the brain, lead to increased tau phosphorylation? One possible answer to this last question is that the infiltrating monocytes modulate the function of resident brain cells such as neurons, astrocytes, and microglia in the context of TBI; in the absence of infiltrating monocytes, the resident cells may release factors that in turn regulate tau phosphorylation. Indeed, we did not detect a reduction in the brain parenchyma occupied by activated microglia in Ccr2<sup>REF</sup>/<sup>RFP</sup> mice (Figs. 1 and 2). Whether these microglia are functionally and molecularly different from microglia in control mice after TBI remains to be determined. Similarly, whether the function of other brain-resident cell types is affected by the absence of CCR2<sup>*</sup> cells in TBI still needs to be examined.

Conclusions

Here we show an unexpected outcome of inhibiting monocyte infiltration into the brain after TBI in Ccr2<sup>REF</sup>/<sup>RFP</sup> mice. Although Ccr2 deletion is protective in terms of lesion volume, axonal pathology, and subsequent behavioral outcomes, it leads to increased phosphorylation and mislocalization of tau protein. The latter has been associated with neurodegenerative diseases and should be carefully considered if strategies aimed at CCR2 signaling continue to be pursued for therapeutic purposes in TBI and other conditions.

Abbreviations

AD: Alzheimer’s disease; ANOVA: analysis of variance; APP: amyloid precursor protein; BBB: blood–brain barrier; CCL2: chemokine (C-C motif) ligand 2; CCR2: chemokine (C-C motif) receptor 2; CNS: central nervous system; CX3CR1: chemokine (C-X3-C motif) receptor 1; CTE: chronic traumatic encephalopathy; dpl: days post injury; GFP: green fluorescent protein; LFP: lateral fluid percussion injury; MAPT: microtubule-associated protein tau; NGS: normal goat serum; PBS: phosphate-buffered saline; PFA: paraformaldehyde; pTau: (hyper)phosphorylated tau; RFP: red fluorescent protein; RT: room temperature; TBI: traumatic brain injury.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SG performed surgeries and injuries, immunofluorescence tissue staining, Western blot, and statistical analysis. DK carried out APP tissue staining and quantification. AK was involved in imaging pTau-stained tissue sections. ONKC participated in design of the study. BTL and RMR participated in design of the study and data interpretation. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by a grant from the National Institutes of Health (R21 NS082798) to BTL and RMR. We thank Anna Retsch for technical assistance.

Received: 8 September 2015 Accepted: 20 November 2015

Published online: 03 December 2015

References

1. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002–2006. Centers for Disease Control and Prevention National Centers for Injury Prevention and Control. 2010.

2. Kiraly MA, Kiraly SJ. Traumatic brain injury and delayed sequelae: a review—traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementia. Sci World J. 2007;7:1768–76.

3. McKeever AE, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Hudson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68(7):709–35.

4. Schofield P, Tang M, Mader K, Bell K, Donneef G, Chun M, et al. Alzheimer’s disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry. 1997;62:119–24.

5. Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC. Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM&R. 2011;3(1025):S460–7.

6. Yi J, Padalino DJ, Chin L, Montenegro P, Cantu RC. Chronic traumatic encephalopathy. Curr Sports Med Rep. 2013;12(1):28–32.

7. Nemetz PN, Leibson C, Naessens JN, Bead M, Kokenem E, Annegers JF, et al. Traumatic brain injury and time to onset of Alzheimer’s disease: a population-based study. Am J Epidemiol. 1999;149(1):32–40.

8. Guo Z, Cupples L, Kurz A, Auerbach S, Volicer L, Chui H, et al. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000;54:1316–23.

9. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007;6:464–79.

10. Kriztawa M, Oddo S, Yamasaki TR, Green KN, Laferla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclooxygenase-dependent S-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci. 2010;30(39):8843–53.

11. Bhaskar K, Konerth M, Koliko-Cochran ON, Cardona A, Ranshoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68(19):31.

12. Ghosh S, Wu MD, Shafeel SS, Kyrkanides S, Laferla FM, Oschowka JA, et al. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci. 2013;33(11):5053–64.
et al. Journal of Neuroinflammation (2015) 12:228

13. Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation. 2012;9:236.

14. Rhodes J. Peripheral immune cells in the pathology of traumatic brain injury? Curr Opin Crit Care. 2011;17:122–30.

15. Kelley BJ, Lilfjeld J, Povlishock JT. Neuroinflammatory responses after experimental diffuse traumatic brain injury. J Neuropathol Exp Neurol. 2007;66(11):989–1001.

16. Morganti-Kossmann MC, Rancan M, Otto V, Stahel PF, Kossmann T. Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock. 2001;16(3):165–77.

17. Gyoneva S, Ransthoﬀ RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends Pharmacol Sci. 2015;36(7):471–80.

18. Giunta B, Obregon D, Vellisetty R, Sanberg PR, Borlongan CV, Tan J. The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention. J Neuroinflammation. 2012;9:185.

19. Dixon CE, Lyeth BG, Povlishock JT, Findling RL, Harmi RM, Marmarou A, et al. A fluid percussion model of experimental brain injury in the rat. J Neurosurg. 1987;67:110–9.

20. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. Nat Rev Neurosci. 2013;14:128–42.

21. Prinz M, Priller J, Siodia S, Ransthoﬀ RM. Heterogeneity of CNS microglia cells and their roles in neurodegeneration. Nat Neurosci. 2011;14(10):1–9.

22. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762–74.

23. Morganti JM, Jopson TD, Liu S, Riparper L-K, Guandique CK, Gupta N, et al. CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by traumatic brain injury. J Neurosci. 2015;35(21):7486–90.

24. Holmin S, Mathiesen T, Biberfeld P. Intracerebral inflammatory response to experimental brain contusia. Acta Neurochir (Wien). 1995;132:10–9.

25. Chu HX, Arumugam TV, Gelderblom M, Magnus T, Drummond GR, Sobey CG. Role of CCR2 in inflammatory conditions of the central nervous system. J Cereb Blood Flow Metab. 2014;34:1425–9.

26. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou C-L, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-ed induced protein knock-in mice. PLoS One. 2010;5(10), e13693.

27. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FMV. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14(9):1142–9.

28. Greer JE, McGinn MJ, Povlishock JT. Diffuse traumatic axonal injury in the mouse induces atrophy, c-Jun activation, and axonal outgrowth in the axotomized neuronal population. J Neurosci. 2011;31(13):5089–105.

29. Cardona AE, Plocco EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917–24.

30. Hsieh CL, Niemi EC, Wang SH, Lee CC, Bingham D, Zhang J, et al. CCR2 deficiency impairs macrophage infiltration and improves cognitive function after traumatic brain injury. J Neurotrauma. 2014;31:1677–88.

31. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110(23):9353–40.

32. Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012;22:142–9.

33. Ormulo BI, DeFossey ST, Minster RL, Kombih MJ, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League Player. Neurosurgery. 2005;57:128–34.

34. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Keutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106–14.

35. Evans TA, Barakauskas DS, Myers J, Hare EG, You J, Ransthoﬀ RM, et al. High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal degeneration in traumatic spinal cord injury. Exp Neurol. 2014;254:109–20.

36. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransthoﬀ RM, et al. Reactive microglia drive tau pathology and contribute to the spreading of tau in the brain. Brain. 2015;138 Pt 6:1738–55.

37. Lee S, Xu G, Jay TR, Bhatta S, Kim K-W, Jung S, et al. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci. 2014;34(57):12538–46.

38. Tran HT, Sanchez L, Esparza TJ, Brody DL. Distinct temporal and anatomical distributions of amyloid-β and tau abnormalities following controlled cortical impact in transgenic mice. PLoS One. 2011;6(9):e25475.

39. Ojo AO, Mouzon B, Greenberg MB, Bachmeier C, Mullan M, Crawford F. Repetitive mild traumatic brain injury augments tau pathology and gli activation in aged hTau mice. J Neuropathol Exp Neurol. 2013;72(2):137–51.

40. Genis L, Chen Y, Shohami E, Michaelson D. Tau hyperphosphorylation in apolipoprotein E-deficient and control mice after closed head injury. J Neurosci Res. 2000;60:559–64.

41. Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014;34(49):16180–93.

42. Holscher C, van Aalten L, Sutherland C. Anaesthesia generates neuronal insulin resistance by inducing hypothermia. BMC Neurosci. 2008;9:100.

43. Panel E, Richter KEG, Bholanet CE, Finley JE, Liu L, Wen Y, et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27(12):3090–7.

44. Run X, Liang Z, Zhang L, Izaki K, Grundke-Iqbal I, Going C-X. Anesthesia induces phosphorylation of tau. J Alzheimers Dis. 2009;16(3):19–26.

45. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice. J Cereb Blood Flow Metab. 2010;30:769–82.

46. Liu S, Zhang L, Wu Q, Wu Q, Wang T. Chemokine CCL2 induces apoptosis in cortex following traumatic brain injury. J Mol Neurosci. 2013;51:1021–9.

47. Israelsen C, Kyberg A, Bengtsson H, Hillered L, E bendal T. Interacting chemokine signals regulate dendritic cells in acute brain injury. PLoS One. 2014;9(8):e104754.